Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...